VYNE Therapeutics (VYNE) News Today $2.55 -0.15 (-5.59%) As of 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Acne Vulgaris Therapeutics Market Size in the 7MM was ~USD 4,256 Million in 2023 and is projected to increase by 2034 | DelveInsightJanuary 24, 2025 | theglobeandmail.comVYNE Therapeutics Updates Corporate Presentation and Pipeline ProgressJanuary 21, 2025 | americanbankingnews.comPatrick G. Lepore Purchases 15,000 Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) StockJanuary 17, 2025 | insidertrades.comVyne therapeutics director Patrick Lepore buys $43,800 in stockJanuary 16, 2025 | msn.comVYNE Therapeutics: Strategic Pipeline Advancements and Promising Clinical OutlookJanuary 14, 2025 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for VYNE Therapeutics (NASDAQ:VYNE)HC Wainwright restated a "buy" rating and set a $5.75 price objective on shares of VYNE Therapeutics in a research report on Tuesday.January 14, 2025 | marketbeat.comVYNE Therapeutics (VYNE) Gets a Buy from BTIGJanuary 8, 2025 | markets.businessinsider.comBuy Rating Justified for VYNE Therapeutics Due to Promising Repibresib Developments and Competitive AdvantagesJanuary 7, 2025 | markets.businessinsider.comVYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligoJanuary 7, 2025 | finance.yahoo.comHC Wainwright Reaffirms "Buy" Rating for VYNE Therapeutics (NASDAQ:VYNE)HC Wainwright reaffirmed a "buy" rating and issued a $5.75 target price on shares of VYNE Therapeutics in a research note on Monday.January 6, 2025 | marketbeat.comVYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental VitiligoJanuary 6, 2025 | globenewswire.comBTIG Initiates a Buy Rating on VYNE Therapeutics (VYNE)January 1, 2025 | markets.businessinsider.comH.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD dataDecember 25, 2024 | finance.yahoo.comVYNE Therapeutics announces results from MAD portion of Phase 1a SAD/MAD trialDecember 23, 2024 | markets.businessinsider.comVYNE Therapeutics Reports Encouraging Phase 1a Data For VYN202December 23, 2024 | markets.businessinsider.comVYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET InhibitorDecember 23, 2024 | globenewswire.comVYNE Therapeutics Inc.December 20, 2024 | thestreet.comBTIG Initiates Coverage of VYNE Therapeutics (VYNE) with Buy RecommendationNovember 19, 2024 | msn.comVYNE Therapeutics initiated with a Buy at BTIGNovember 18, 2024 | markets.businessinsider.comVYNE Therapeutics initiated with a Buy at BTIG on I&I potentialNovember 18, 2024 | markets.businessinsider.comVYNE Therapeutics Advances Clinical Pipeline in Q3 2024November 9, 2024 | markets.businessinsider.comVYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsNovember 9, 2024 | finance.yahoo.comVYNE Therapeutics: Promising Clinical Progress and Financial Stability Support Buy RatingNovember 7, 2024 | markets.businessinsider.comVYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | tmcnet.comRheumatoid Arthritis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersOctober 24, 2024 | theglobeandmail.comVera Therapeutics’ Atacicept: Promising Clinical Data and Strategic Expansion Fuel Buy RatingOctober 3, 2024 | markets.businessinsider.comBuy Rating for VYNE Therapeutics Backed by Promising Early Phase Results and Strong Clinical Development TrajectorySeptember 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for VYNE Therapeutics Amid Promising Early Data for VYN202September 12, 2024 | markets.businessinsider.comVYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET InhibitorSeptember 12, 2024 | globenewswire.comVYNE Therapeutics to Participate in September Investor ConferencesSeptember 3, 2024 | uk.finance.yahoo.comVYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsAugust 16, 2024 | finance.yahoo.comBuy Rating for VYNE Therapeutics Amid Strong Financial Footing and Promising Clinical TrialsAugust 15, 2024 | markets.businessinsider.comVYNE Therapeutics Inc.: VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | finanznachrichten.deBuy Rating Affirmed for VYNE Therapeutics on Strong Financials and Promising Drug TrialsAugust 14, 2024 | markets.businessinsider.comVYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024August 14, 2024 | investorplace.comVYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | globenewswire.comBuy Rating for Viridian Therapeutics Backed by Physician Preference and Treatment Potential for TEDAugust 6, 2024 | markets.businessinsider.comVYNE Therapeutics IncJuly 20, 2024 | morningstar.comVYNE Therapeutics to Participate in Leerink Partners Therapeutics ForumJune 26, 2024 | globenewswire.comVYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202June 13, 2024 | globenewswire.comBuy Rating Affirmed for VYNE Therapeutics on Promising Clinical Advancements and Strategic Pipeline ProgressionMay 16, 2024 | markets.businessinsider.comBuy Rating for VYNE Therapeutics on Strong Financial Footing and Promising Clinical PipelineMay 9, 2024 | markets.businessinsider.comVYNE Stock Earnings: VYNE Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | investorplace.comVYNE Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | globenewswire.comVYNE Therapeutics receives FDA approval for trial of VYN202May 7, 2024 | finance.yahoo.comBuy Rating Affirmed for VYNE Therapeutics on Promising Drug Development Milestones and Positive Clinical DataMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for VYNE Therapeutics Amidst Favorable IND Clearance and Promising VYN202 DevelopmentMay 7, 2024 | markets.businessinsider.comVYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET InhibitorMay 6, 2024 | globenewswire.comVYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual MeetingMay 1, 2024 | globenewswire.comVYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth PlansApril 13, 2024 | finance.yahoo.com Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address VYNE Media Mentions By Week VYNE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VYNE News Sentiment▼0.840.75▲Average Medical News Sentiment VYNE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VYNE Articles This Week▼21▲VYNE Articles Average Week Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NBTX News Today SCPH News Today ADCT News Today TIL News Today SLN News Today FATE News Today KYTX News Today BMEA News Today IPHA News Today ADAP News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VYNE) was last updated on 1/29/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredMan Who Called Nvidia Says: “Your Retirement Is Inside This Building.”In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VYNE Stock Alerts